Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $608000.0.

  • Abeona Therapeutics' Depreciation & Amortization (CF) rose 2484.6% to $608000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 1375.26%. This contributed to the annual value of $2.0 million for FY2024, which is 1241.26% down from last year.
  • Per Abeona Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $608000.0 for Q3 2025, which was up 2484.6% from $544000.0 recorded in Q2 2025.
  • Abeona Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $824000.0 during Q2 2021, with a 5-year trough of $487000.0 in Q2 2024.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $615000.0 (2023), whereas its average is $648473.7.
  • In the last 5 years, Abeona Therapeutics' Depreciation & Amortization (CF) crashed by 6043.58% in 2021 and then skyrocketed by 2484.6% in 2025.
  • Over the past 5 years, Abeona Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $807000.0 in 2021, then decreased by 9.67% to $729000.0 in 2022, then crashed by 32.65% to $491000.0 in 2023, then grew by 9.78% to $539000.0 in 2024, then grew by 12.8% to $608000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $608000.0 in Q3 2025, compared to $544000.0 in Q2 2025 and $534000.0 in Q1 2025.